To evaluate the role of preoperative neutrophils to lymphocytes ratio (NLR) as a predictor for the response to BCG in patients with non-muscle invasive bladder cancer (NMIBC).
Materials:
Nighty six patients with NMIBC were prospectively included in our study. Our study population was classified into two groups, based on pre-operative (NLR) either ⩽ or > 3. After receiving BCG, patients were followed up for 3 years to evaluate the correlation between BCG failure and (NLR).
Results:
Nighty two patients were evaluated at the end of our study. The NLR > 3 group of patients showed a higher age and T stage compared to the NLR ⩽ 3 group with a significant difference. BCG failure was reported to be higher in the NLR > 3 group with a failure rate of 66.7% compared to 28.3% in the other group (p-value < 0.001). Time to failure in NLR > 3 group compared to NLR ⩽ 3 group was 10.44 ± 4.3 and 15 ± 3.9 months respectively with a (p-value = 0.002). Univariate and multivariate logistic regression revealed that the most significant predictors of BCG failure were NLR > 3, Initial T stage, and age respectively.
Conclusion:
BCG response is highly affected by the NLR, with a higher failure rate with NLR > 3.
SoukupVČapounOCohenD, et al. Risk stratification tools and prognostic models in non–muscle-invasive bladder cancer: a critical assessment from the european association of urology non-muscle-invasive bladder cancer guidelines panel. Eur Urol Focus2020; 6(3): 479–489.
2.
BabjukMBurgerMCapounOCohenDCompératEMDominguez EscrigJL, et al. European association of urology guidelines on non–muscle-invasive bladder cancer (Ta, T1, and Carcinoma in Situ). Eur Urol [Internet]2022; 81(1): 75–94. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0302283821019783
3.
LightfootAJRosevearHMO’DonnellMA.Recognition and treatment of BCG failure in bladder cancer. Sci World J2011; 11: 602–613.
4.
WitjesJA.Follow-up in non-muscle invasive bladder cancer: facts and future. World J Urol2021; 39(11): 4047–4053.
5.
RitchCRVelasquezMCKwonD, et al. Use and validation of the AUA/SUO risk grouping for nonmuscle invasive bladder cancer in a contemporary cohort. J Urol2020; 203(3): 505–511.
6.
LebacleCLoriotYIraniJ.BCG-unresponsive high-grade non-muscle invasive bladder cancer: what does the practicing urologist need to know?World J Urol2021; 39(11): 4037–4046.
7.
ZhaoRShanJNieL, et al. The predictive value of the ratio of the product of neutrophils and hemoglobin to lymphocytes in non-muscular invasive bladder cancer patients with postoperative recurrence. J Clin Lab Anal2021; 35(8): 1–8.
8.
RacioppiMGianfrancescoLDRagoneseM, et al. Can neutrophil-to-lymphocyte ratio predict the response to BCG in high-risk non muscle invasive bladder cancer?Int Braz J Urol2019; 45(2): 315–324.
9.
D’AndreaDMoschiniMGustK, et al. Prognostic role of neutrophil-to-lymphocyte ratio in primary non–muscle-invasive bladder cancer. Clin Genitourin Cancer2017; 15(5): e755–e764.
10.
FavillaVCastelliTUrzìD, et al. Neutrophil to lymphocyte ratio, a biomarker in non-muscle invasive bladder cancer: a single-institutional longitudinal study. Int Braz J Urol2016; 42(4): 685–693.
11.
MiyakeMKitamuraHNishimuraN, et al. Validation of non-muscle-invasive bladder cancer risk stratification updated in the 2021 European Association of Urology guidelines. BJUI Compass2024; 5(2): 269–280.
12.
BabjukMBurgerMCompératEM, et al. European association of urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ) - 2019 update. Eur Urol2019; 76(5): 639–657.
13.
ŚlusarczykAPiotrZGarbasK, et al. Blood count-derived inflammatory markers predict time to Bacillus Calmette-Guérin failure in high-risk non-muscle-invasive bladder cancer. Arch Med Sci2021; 17: 1–9.
14.
HatogaiKSweisRF.The tumor microenvironment of bladder cancer. In: BirbrairA (eds.) Tumor microenvironments in organs. Advances in experimental medicine and biology, vol 1296. Cham: Springer, 2020, pp.275–290.
15.
HanJGuXLiY, et al. Mechanisms of BCG in the treatment of bladder cancer-current understanding and the prospect. Biomed Pharmacother2020; 129: 110393.
16.
UleriAHurleRContieriR, et al. Combination of AST to ALT and neutrophils to lymphocytes ratios as predictors of locally advanced disease in patients with bladder cancer subjected to radical cystectomy: results from a single-institutional series. Urol J2022; 89(3): 363–370.
17.
BolatDBaltaciSAkgulM, et al. Predictive role of the systemic immune inflammation index for intravesical BCG response in intermediate- and high-risk non-muscle-invasive bladder cancer. Urol Int2023; 107(6): 617–623.
18.
ChakraMALassilaREl BeayniN, et al. Prognostic role of the neutrophil/lymphocyte ratio in high-risk BCG-naïve non-muscle-invasive bladder cancer treated with intravesical gemcitabine/docetaxel. BJU Int2025; 135: 125–132.
19.
YukHDJeongCWKwakC, et al. Elevated neutrophil to lymphocyte ratio predicts poor prognosis in non-muscle invasive bladder cancer patients: initial intravesical bacillus calmette-guerin treatment after transurethral resection of bladder tumor setting. Front Oncol2019; 8: 1–8.
20.
ManoRBanielJShoshanyO, et al. Neutrophil-to-lymphocyte ratio predicts progression and recurrence of non – muscle-invasive bladder cancer. Urol Oncol Semin Orig Investig2015; 33(2): 67.e1–67.e7.
21.
GetzlerIBahouthZNativO, et al. Preoperative neutrophil to lymphocyte ratio improves recurrence prediction of non-muscle invasive bladder cancer. BMC Urol2018; 18(1): 90.
22.
WangRYanYLiuS, et al. Comparison of preoperative neutrophil-lymphocyte and platelet-lymphocyte ratios in bladder cancer patients undergoing radical cystectomy. Biomed Res Int2019; 2019(1): 3628384.
23.
RouprêtMBabjukMCompératE, et al. European association of urology guidelines on upper urinary tract urothelial carcinoma: 2017 update. Eur Urol2018; 73(1): 111–122.
